Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Key takeaways of Q3FY22 quarter & conference call highlights
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
